A5031662570- Epigenetics and DNA Methylation
- Glioma Diagnosis and Treatment
- RNA Research and Splicing
- Genomics and Chromatin Dynamics
- Genomic variations and chromosomal abnormalities
- Cancer Genomics and Diagnostics
- Immune Response and Inflammation
- Antimicrobial Peptides and Activities
- Histone Deacetylase Inhibitors Research
- Ferroptosis and cancer prognosis
- RNA modifications and cancer
- Cancer-related gene regulation
- NF-κB Signaling Pathways
- Cancer-related molecular mechanisms research
- Genetic factors in colorectal cancer
- MicroRNA in disease regulation
Centre Hospitalier Universitaire de Sherbrooke
2023-2025
Université de Sherbrooke
2020-2025
National Institute of Mental Health and Neurosciences
2019
Objective: High grade glioma (HGG) patients show poor prognosis and survival. Promoter methylation of MGMT gene induces altered profile across cell cycle regulating genes. Correlating the promoter status between important tumor suppressor genes could enhance current understanding progression. Methods: We analysed individual concurrent statuses’ three genes, MGMT, TP53 CDKN2A in different types HGG their probable effect on progression free MS-PCR was used to analyse statuses from 48...
How cell-type-specific chromatin landscapes emerge and progress during metazoan ontogenesis remains an important question. Transcription factors are expressed in a manner recruit chromatin-regulatory machinery to specific genomic loci. In contrast, proteins broadly assumed exert the same intrinsic function across cell types. However, human genetics studies have revealed unexpected vulnerability of neurodevelopment factor mutations with unknown mechanisms. Here, we report that 14 regulators...
Glioma is the most common brain tumor of glial cells with a highly infiltrative nature. A grade IV glioblastoma malignant and aggressive presenting complex mutations very high genomic alteration status. Glioblastoma patients have fastest progression compared to other cancer poor survival. Methylation status MGMT, gene encoding DNA repair enzyme, only known promising biomarker. There need look for new biomarkers in similar functional pathways. Two mismatch pathway (MMR) genes, hMSH2, hMSH6,...
Abstract Background Hypermethylation of 06-methylguanine DNA methyltransferase ( MGMT) promoter seen in high grade gliomas (HGG) leads to the accumulation O6-meG damage which mispairs with thymine, requiring recognition by mismatch repair protein dimer MutSα, whose primary component is coded Human MutS homolog 2 hMSH2) . necessitates interaction/combined action MGMT andhMSH2 maintain genomic stability. Analysis correlation between methylation and hMSH2 mRNAexpression HGG their role prognosis...
<h3>Background</h3> Squamous cell lung cancer (SCLC) is the second most common type of cancer. Treatment complicated due to lack mutated molecular targets.<sup>1</sup> Radiotherapy (RT) commonly used treat SCLC, but relapse and tumor progression are common. The combination immunotherapy (IT) with RT can enhance effect observed alone.<sup>2</sup> Effective IT requires an understanding pathways that synergize kill in SCLC. Our lab has identified Toll-like receptor 3 (TLR3) as a molecule...
Glioblastoma Multiforme (GBM) is the most malignant brain tumor with highest fraction of genome alterations (FGA), manifesting poor disease-free status (DFS) and overall survival (OS). Methylation O-6-methylguanine-DNA methyltransferase (MGMT) promising biomarker known to have better therapy prediction prognosis. However, MGMT’s predictive abilities are effective in only 50-60% GBM patients, suggesting a need identify new biomarkers. We explored The Cancer Genome Atlas (TCGA) cBioportal...